BullFrog AI Holdings, Inc. BFRG
AI Holdings, Inc. was incorporated in the State of Nevada in February 2020. BullFrog AI Holdings, Inc. is the parent company of BullFrog
AI, Inc. and BullFrog AI Management, LLC, which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All our operations
are currently conducted through BullFrog AI Holdings, Inc. The Company's principal business address is 325 Ellington Blvd, Unit
of BullFrog AI, Inc.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $116.7K | — | $65.0K | $10.0K | — | — |
| Cost of revenue | $94.8K | — | $5.2K | $800 | — | — |
| Gross profit | $21.9K | — | $59.8K | $9.2K | — | — |
| R&D | $1.8M | $2.2M | $1.4M | $609.3K | $25.0K | — |
| SG&A | $4.8M | $5.0M | $4.0M | $1.9M | $327.3K | — |
| Total operating expenses | $6.6M | $7.2M | $5.4M | $2.5M | $555.4K | — |
| Operating income | -$6.6M | -$7.2M | -$5.4M | -$2.5M | -$555.4K | — |
| Interest expense | $5.6K | $18.2K | $79.1K | $347.1K | $40.4K | — |
| Net income | -$6.5M | -$7.0M | -$5.4M | -$2.8M | -$585.8K | — |
| EPS, basic | -0.63 | -0.85 | -0.89 | -0.70 | -14.00 | — |
| EPS, diluted | -0.63 | -0.85 | -0.89 | -0.70 | — | — |
| Shares, diluted (wtd. avg.) | $10.3M | $8.2M | $6.0M | $4.0M | $4.1M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $2.2M | $5.4M | $2.6M | $57.7K | $10.0K | $5.0K |
| Total current assets | $2.6M | $5.5M | $2.8M | $72.7K | $10.0K | — |
| Property, plant and equipment | $2.5K | $4.2K | $6.0K | $7.7K | — | — |
| Total assets | $2.8M | $5.6M | $2.8M | $80.4K | $10.0K | — |
| Accounts payable | $168.2K | $435.9K | $103.7K | $544.0K | $68.6K | — |
| Short-term debt | — | — | — | — | $34.0K | — |
| Total current liabilities | $672.0K | $588.1K | $184.3K | $3.1M | $1.0M | — |
| Total liabilities | $672.0K | $588.1K | $184.3K | $3.1M | $1.0M | — |
| Retained earnings | -$23.3M | -$16.8M | -$9.8M | -$4.4M | -$1.6M | — |
| Total equity | $2.1M | $5.0M | $2.6M | -$3.1M | -$1.0M | -$540.5K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.5M | -$5.6M | -$6.0M | -$910.9K | -$382.4K | — |
| Depreciation and amortisation | $1.7K | $1.7K | $1.7K | $1.0K | — | — |
| Stock-based compensation | $1.0M | $943.6K | $631.5K | $340.2K | $99.0K | — |
| Capital expenditure | — | — | — | $8.7K | — | — |
| Investing cash flow | — | — | — | -$8.7K | — | — |
| Financing cash flow | $2.4M | $8.4M | $8.6M | $967.3K | $387.4K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-011644.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |